Acceleron Pharma hebt up!

Hintergrund: Acceleron’s PAH drug sotatercept hits the mark in phase 2

https://www.fiercebiotech.com/biotech/...otatercept-hits-mark-phase-2

http://acceleronpharma.com/

 

Phase2 Sotatercept erreicht primären und sekundären Endpunkt

https://www.pharmaceutical-business-review.com/...erial-hypertension/

 

positive Sotatercept Studiendaten in PAH

https://xconomy.com/boston/2020/01/28/...-shows-early-promise-in-pah/

 

FDA genehmigt beschleunigtes Zulassungsverfahren (Sotatercept)

https://www.pharmaceutical-business-review.com/...erial-hypertension/

 

~400 Mio. $ Offering geplant

http://investor.acceleronpharma.com/news-releases/...g-common-stock-2

 

Läuft rund. Das Offering Anfang Juli hatte insgesamt ~493 Mio. $ eingebracht.

• 5,59 Mio. neue Aktien zu je 92,50$
  

http://investor.acceleronpharma.com/news-releases/...common-stock-and

 

https://www.benzinga.com/general/biotech/21/02/...s-associated-anemia